1D40 - Chikungunya Virus Disease: Complete Clinical Coding Guide

1. Introduction

Chikungunya virus disease represents an arbovirus of growing importance in global public health, characterized by debilitating clinical manifestations that can persist for prolonged periods. Transmitted through the bite of mosquitoes of the genus Aedes (mainly Aedes aegypti and Aedes albopictus), this viral infection has expanded its geographic distribution in recent decades, affecting millions of people in tropical and subtropical regions around the world.

The name "Chikungunya" derives from a word in the Makonde language that means "that which bends over," a direct reference to the characteristic posture adopted by patients due to the intense joint pain that accompanies the infection. This distinctive clinical manifestation, combined with acute fever, constitutes the typical presentation of the disease, although the spectrum of symptoms can vary considerably among different patients.

The clinical relevance of Chikungunya transcends its acute phase. A significant proportion of patients develops chronic symptoms, particularly persistent arthralgia, which can last months or even years after the initial infection. This potential for chronicity directly impacts patients' quality of life, work productivity, and health systems.

Appropriate coding of this condition using ICD-11 code 1D40 is fundamental for accurate epidemiological surveillance, appropriate allocation of health resources, planning of vector control measures, and clinical research. Correct documentation allows tracking of epidemiological trends, early identification of outbreaks, and evaluation of the effectiveness of public health interventions.

2. Correct ICD-11 Code

Code: 1D40

Description: Chikungunya virus disease

Parent category: Some arthropod-borne viral fevers

The code 1D40 in ICD-11 specifically identifies infection caused by Chikungunya virus, an alphavirus of the Togaviridae family. This code encompasses all clinical manifestations of the disease, from asymptomatic forms to severe complications.

The official definition establishes that infection occurs through the bite of Aedes mosquitoes, with fever and concomitant arthralgia representing common specific signs. The infection may present with nonspecific symptoms that overlap with dengue, including headache, rash, and myalgia. Free virions are transported by blood to the liver (causing hepatocyte apoptosis), muscles, joints, and secondary lymphoid organs (lymphadenopathy), where the virus replicates.

Viral replication is associated with infiltration of mononuclear cells, including macrophages, which underlies the debilitating pain experienced in muscles and joints, potentially persisting for months to years after infection. A small percentage of infected individuals remains asymptomatic, being more common in patients under 25 years of age. Age over 40 years constitutes a risk factor for chronicity of symptoms. Encephalitis, Guillain-Barré syndrome, and arthritis represent rare complications of Chikungunya virus infection.

3. When to Use This Code

Code 1D40 should be applied in specific clinical scenarios where there is confirmation or strong clinical-epidemiological suspicion of Chikungunya virus infection:

Scenario 1: Acute fever with intense polyarthralgia in endemic area A 45-year-old patient presents with sudden-onset fever (39-40°C) accompanied by bilateral and symmetric joint pain, primarily affecting wrists, ankles, knees, and small joints of the hands. The patient reports that the intensity of pain is incapacitating, hindering basic activities such as walking or grasping objects. There is a history of exposure in an area with known virus circulation and presence of Aedes mosquitoes. This is the classic scenario that justifies code 1D40, especially if confirmed by serological tests (anti-Chikungunya IgM) or positive RT-PCR.

Scenario 2: Acute febrile syndrome with maculopapular rash A young patient develops an acute febrile condition associated with a maculopapular rash that begins on the trunk and spreads to the extremities, accompanied by arthralgia, retro-orbital headache, and myalgia. The presentation occurs during a documented Chikungunya outbreak in the community. Even without immediate laboratory confirmation, the epidemiological context and constellation of symptoms justify coding 1D40 for surveillance and clinical management purposes.

Scenario 3: Chronic arthralgia following confirmed infection A patient with laboratory-confirmed Chikungunya diagnosis six months prior returns for consultation with complaints of persistent joint pain, morning stiffness, and intermittent joint swelling, particularly in the hands and feet. The persistence of articular symptoms after the acute phase of infection in a patient over 40 years of age represents a recognized manifestation of the disease and should be coded as 1D40, and may be accompanied by additional codes to describe specific musculoskeletal manifestations.

Scenario 4: Confirmed infection in pregnant woman A pregnant woman in the third trimester presents with high fever, intense arthralgia, and rash, with laboratory confirmation of acute Chikungunya infection. This scenario requires code 1D40 as the primary diagnosis, with possible need for additional codes related to pregnancy, considering the risk of vertical transmission, especially if infection occurs near delivery.

Scenario 5: Associated neurological manifestations A patient diagnosed with Chikungunya develops encephalitis or Guillain-Barré syndrome during or shortly after the acute phase of infection. Although these complications are rare, when they occur in the context of confirmed or highly suspected Chikungunya infection, code 1D40 should be used, accompanied by specific codes for the neurological complications.

Scenario 6: Asymptomatic infection detected on screening During epidemiological investigation of an outbreak or seroprevalence study, an individual presents with positive serology for Chikungunya (IgG) without report of previous compatible symptoms. Although less common in routine clinical practice, this scenario also justifies code 1D40, documenting previous asymptomatic infection.

4. When NOT to Use This Code

It is essential to distinguish Chikungunya from other conditions that may present with similar clinical manifestations but require different codes:

Dengue (code 1D2Z): Although dengue and Chikungunya share the same vector and may coexist in endemic areas, dengue typically presents with more pronounced leukopenia, thrombocytopenia, hemorrhagic manifestations, and intense retro-orbital pain. Arthralgia in dengue is generally less intense and less persistent than in Chikungunya. When laboratory diagnosis confirms dengue, the appropriate code from category 1D2Z should be used, not 1D40.

Rheumatoid arthritis or other chronic inflammatory arthropathies: Patients with chronic joint pain without documented history of acute Chikungunya infection should not receive code 1D40. Chronic inflammatory arthropathies have specific codes in the chapter on musculoskeletal diseases. Differentiation is based on clinical history of acute febrile phase, prior laboratory confirmation, and temporal pattern of evolution.

Fever of undetermined etiology without confirmation: Acute febrile syndrome in a patient without known epidemiological exposure, without characteristic arthralgia, and without laboratory confirmation should not be coded as 1D40. In these cases, codes for fever of undetermined origin or other differential diagnoses are more appropriate until diagnostic clarification.

Other arboviruses: Infections by other arthropod-borne viruses, such as Oropouche virus (1D43), O'nyong-nyong fever (1D42), or Colorado tick fever (1D41), have specific codes and should not be coded as 1D40, even when there is symptom overlap.

Coinfections: When there is laboratory confirmation of coinfection (for example, Chikungunya and dengue simultaneously), both codes should be used. Code 1D40 alone should not be used when another infection is documentedly present.

5. Step-by-Step Coding Process

Step 1: Assess diagnostic criteria

The diagnosis of Chikungunya is based on clinical, epidemiological, and laboratory criteria. Begin by assessing the presence of characteristic clinical manifestations: sudden onset fever (frequently high), intense arthralgia (typically polyarticular, bilateral and symmetric), which may be accompanied by joint edema, maculopapular rash, myalgia, headache and fatigue.

Investigate the epidemiological context: recent exposure in an area with active Chikungunya transmission, presence of confirmed cases in the community, time of year favorable to Aedes mosquito proliferation. A history of mosquito bites, although frequently not recalled by patients, reinforces suspicion.

Laboratory confirmation is ideal and can be obtained through: RT-PCR (detects viral RNA, more sensitive in the first 5-7 days of symptoms), IgM serology (positive from the 5th-7th day of illness, persisting for weeks to months) and IgG serology (indicates past infection, with seroconversion or increase in titers in paired samples confirming recent infection).

Nonspecific complementary tests may show mild leukopenia, lymphopenia, mild to moderate thrombocytopenia and elevation of liver enzymes, assisting in differential diagnosis.

Step 2: Verify specifiers

Although code 1D40 does not have formal subcategories in the current ICD-11 structure, it is important to document specific characteristics that influence management and prognosis:

Phase of illness: Acute (first 10-14 days), subacute (up to 3 months) or chronic (beyond 3 months). This temporal distinction is clinically relevant and should be included in clinical documentation.

Severity: Mild cases (symptoms manageable on an outpatient basis), moderate (intense symptoms requiring potent analgesia) or severe (complications such as neurological manifestations, decompensation of comorbidities, need for hospitalization).

Presence of complications: Neurological manifestations (encephalitis, meningoencephalitis, Guillain-Barré syndrome, myelitis), cardiovascular (myocarditis, arrhythmias), ophthalmological (uveitis, retinitis) or dermatological (bullous lesions, hyperpigmentation).

Risk factors for chronicity: Age over 40 years, presence of prior arthropathy, intensity of arthralgia in the acute phase, comorbidities such as diabetes or hypertension.

Step 3: Differentiate from other codes

1D41 - Colorado tick fever: Transmitted by ticks (not mosquitoes), occurs in specific mountainous regions, presents characteristic biphasic fever pattern (saddleback fever) and rarely causes intense and persistent arthralgia. History of tick exposure and specific geographic area are key elements of differentiation.

1D42 - O'nyong-nyong fever: Although clinically very similar to Chikungunya (also causes fever and polyarthralgia), it is caused by a different virus and has geographic distribution restricted mainly to East Africa. Definitive differentiation requires specific laboratory confirmation, but geographic context is fundamental.

1D43 - Oropouche virus disease: Transmitted by Culicoides mosquitoes (not Aedes), presents with fever, intense headache and myalgia, but arthralgia is not a prominent characteristic feature. Photophobia and dizziness are more common. The absence of intense and persistent arthralgia helps differentiate from Chikungunya.

Specific laboratory differentiation through RT-PCR or directed serology is the gold standard when available. In the absence of laboratory confirmation, the clinical-epidemiological context guides coding.

Step 4: Required documentation

For appropriate coding of 1D40, the medical record must contain:

Mandatory documentation checklist:

• Date of symptom onset
• Detailed description of clinical manifestations (fever, arthralgia with specific location, rash, other symptoms)
• History of epidemiological exposure (area with active transmission, cases in the community)
• Results of specific laboratory tests (RT-PCR, IgM/IgG serology) when performed
• Relevant complementary tests (complete blood count, liver function)
• Phase of illness (acute, subacute, chronic)
• Presence or absence of complications
• Risk factors for chronicity
• Differential diagnoses considered and excluded
• Treatment instituted
• Follow-up plan

Clear and complete documentation not only justifies coding, but also facilitates continuity of care, allows for accurate epidemiological analyses and supports public health decisions.

6. Complete Practical Example

Clinical Case:

A 52-year-old female patient, previously healthy, presents to the emergency department with a complaint of high fever (39.5°C) that started three days ago, associated with intense pain in multiple joints. She reports that the pain began in the hands and wrists, rapidly extending to the knees, ankles, and feet, with progressively increasing intensity. She describes the pain as "unbearable," preventing her from performing basic activities such as holding utensils, walking, or dressing without assistance.

In addition to fever and arthralgia, the patient reports moderate frontal headache, generalized muscle pain, and the appearance of reddish spots on the trunk on the second day of symptoms, which spread to the arms and legs. She denies bleeding, severe abdominal pain, or respiratory symptoms. She mentions that several neighbors presented with a similar condition in recent weeks, and that the region where she lives has a large mosquito infestation.

On physical examination: patient in fair general condition, febrile (38.8°C), hydrated, alert and oriented. Diffuse maculopapular rash on trunk and extremities. Mild edema in metacarpophalangeal and interphalangeal joints bilaterally, with pain on passive and active mobilization. Edema and pain in ankles. Absence of petechiae or signs of bleeding. Tourniquet test negative. Absence of meningeal signs or focal neurological deficits.

Laboratory tests ordered:

• Complete blood count: leukocytes 3,200/mm³ (relative lymphopenia), hemoglobin 13.2 g/dL, platelets 142,000/mm³
• Transaminases: AST 78 U/L, ALT 92 U/L
• RT-PCR for Chikungunya: positive
• IgM serology for Chikungunya: positive
• RT-PCR for dengue: negative
• Serology for dengue: IgG positive (previous infection), IgM negative

Coding Step by Step:

Analysis of criteria: The patient presents with the classic triad of Chikungunya: high fever of sudden onset, intense and symmetric polyarthralgia, and rash. The epidemiological context (cases in the community, area with Aedes mosquitoes) reinforces the suspicion. Laboratory confirmation through positive RT-PCR and IgM establishes the definitive diagnosis.

The intensity of arthralgia, described as incapacitating, and the distribution pattern (small joints of the hands, wrists, knees, ankles) are characteristic. The joint edema observed on physical examination is a common finding in the acute phase.

Complementary tests show mild leukopenia and discrete thrombocytopenia, compatible with Chikungunya, in addition to mild elevation of transaminases, indicating hepatic involvement. The exclusion of dengue through negative RT-PCR and absence of IgM is important to avoid incorrect coding.

The patient's age (52 years) represents a risk factor for chronicity of articular symptoms, information relevant to prognosis and follow-up planning.

Code chosen: 1D40 - Disease caused by Chikungunya virus

Complete justification: Code 1D40 is the correct and only necessary code for this case because:

1. There is definitive laboratory confirmation of acute Chikungunya virus infection through positive RT-PCR and positive IgM serology
2. Clinical manifestations are typical and complete: high fever, intense and symmetric polyarthralgia, maculopapular rash
3. The epidemiological context supports the diagnosis (cases in the community, endemic area)
4. Other arboviruses were excluded laboratorially (negative dengue RT-PCR)
5. There are no complications requiring additional codes (no neurological, cardiovascular, or other serious complications)
6. The patient is in the acute phase of the disease (three days of symptoms)

Complementary codes: In this specific case, no additional mandatory codes are necessary. Code 1D40 adequately captures the primary diagnosis. However, in expanded documentation, additional codes could be considered to describe specific symptoms if relevant for billing or detailed record-keeping (codes for arthralgia, fever), but code 1D40 as the primary diagnosis is sufficient for clinical and epidemiological purposes.

The follow-up plan should include reevaluation in 7-10 days to monitor progression, guidance on adequate analgesia, hydration, relative rest, and warning signs for complications. Given the risk factor for chronicity (age > 40 years), the patient should be informed about the possibility of persistent articular symptoms and advised regarding long-term follow-up if necessary.

7. Related Codes and Differentiation

Within the Same Category:

1D41: Colorado tick fever

• When to use vs. 1D40: Use 1D41 when there is a history of tick bite or exposure in an endemic mountainous area (mainly mountainous regions of North America), with presentation of characteristic biphasic fever (saddleback pattern: fever for 2-3 days, remission for 1-2 days, return of fever). Arthralgia is not a prominent manifestation.
• Main difference: Vector (tick vs. mosquito), specific geographic distribution, characteristic biphasic fever pattern, absence of intense and persistent arthralgia.

1D42: O'nyong-nyong fever

• When to use vs. 1D40: Use 1D42 when there is specific laboratory confirmation of O'nyong-nyong virus infection or when the epidemiological context clearly indicates this etiology (documented outbreaks in specific regions of East Africa). Clinically very similar to Chikungunya, with fever and polyarthralgia.
• Main difference: Specific viral etiology (requires laboratory confirmation for definitive distinction), more restricted geographic distribution, more prominent cervical lymphadenopathy. In practice, definitive differentiation requires specific laboratory tests.

1D43: Oropouche virus disease

• When to use vs. 1D40: Apply 1D43 when there is confirmation of Oropouche virus infection or suggestive epidemiological context (areas with known transmission, generally Amazonian regions and tropical areas). Typical presentation includes sudden fever, intense headache, myalgia, photophobia and dizziness, but arthralgia is not a prominent characteristic manifestation.
• Main difference: Different vector (Culicoides mosquitoes, not Aedes), absence of intense and persistent arthralgia as main manifestation, more frequent presence of photophobia and dizziness, generally shorter-lasting symptoms.

Important Differential Diagnoses:

Dengue (1D2Z): Although it shares the same vector and many symptoms (fever, headache, myalgia, rash), dengue is differentiated by more intense retro-orbital pain, hemorrhagic manifestations (petechiae, epistaxis, gingival bleeding), more pronounced thrombocytopenia, more marked leukopenia, and less intense and less persistent arthralgia. Positive tourniquet test suggests dengue. Specific laboratory confirmation is essential.

Zika (1D47): Generally lower or absent fever, more prominent pruritic rash, characteristic non-purulent conjunctivitis, less intense arthralgia. Special concern in pregnant women due to risk of fetal microcephaly.

Rheumatoid arthritis: Chronic inflammatory arthropathy without initial acute febrile phase, prolonged morning stiffness pattern, gradual progression, characteristic radiographic changes, rheumatoid factor and anti-CCP frequently positive.

Leptospirosis: Fever, intense myalgia (especially in calves), headache, but arthralgia is not prominent. History of exposure to contaminated water, jaundice in severe forms, leukocytosis (not leukopenia).

8. Differences with ICD-10

In ICD-10, Chikungunya was coded as A92.0 (Chikungunya virus disease), located in category A92 (Other viral fevers transmitted by mosquitoes).

Main changes in ICD-11:

Alphanumeric code change: From A92.0 to 1D40, reflecting the new organizational structure of ICD-11, which uses a different alphanumeric system, allowing greater flexibility and expansion capacity.

Categorical reorganization: In ICD-11, code 1D40 is inserted in the category "Some viral fevers transmitted by arthropods", maintaining logical grouping with other arboviruses, but with improved hierarchical structure.

Expanded definition: ICD-11 provides a more detailed and clinically oriented definition, including information on pathogenesis (viral transport through blood, hepatocyte apoptosis, mononuclear cell infiltration), chronic manifestations, risk factors for chronicity (age > 40 years), and rare complications (encephalitis, Guillain-Barré syndrome). This expansion facilitates precise coding and clinical understanding.

Practical impact of these changes:

The transition to ICD-11 requires updating health information systems, training of coding professionals, and adaptation of institutional protocols. The more detailed definition facilitates identification of cases that should receive code 1D40, reducing ambiguities.

For purposes of epidemiological surveillance and longitudinal comparative studies, it is important to maintain correspondence tables between ICD-10 and ICD-11, recognizing that A92.0 corresponds to 1D40. Greater specificity in ICD-11 potentially allows for more refined epidemiological analyses, particularly regarding chronic manifestations and complications.

Health systems in transition may require a period of parallel use of both classifications, with appropriate mapping to ensure continuity of epidemiological and administrative data.

9. Frequently Asked Questions

1. How is Chikungunya diagnosed?

The diagnosis of Chikungunya is based on a combination of clinical, epidemiological, and laboratory criteria. Clinically, the presence of sudden-onset fever associated with intense arthralgia, especially if polyarticular, bilateral, and symmetric, in a patient with exposure in an endemic area raises strong suspicion. Laboratory confirmation can be obtained through RT-PCR (detects viral RNA, more sensitive in the first 5-7 days of symptoms) or serology (positive IgM from the 5th-7th day, IgG indicates past or recent infection if seroconversion occurs). Nonspecific tests such as complete blood count may show leukopenia and mild thrombocytopenia, aiding in differential diagnosis. In endemic areas during outbreaks, clinical-epidemiological diagnosis may be sufficient for initial management, although laboratory confirmation is ideal for epidemiological surveillance.

2. Is treatment available in public health systems?

There is no specific antiviral treatment for Chikungunya. Management is essentially symptomatic and supportive, which facilitates its availability in public health systems. Treatment includes rest, adequate hydration, use of analgesics and antipyretics (acetaminophen is preferred; nonsteroidal anti-inflammatory drugs should be avoided until dengue is excluded due to bleeding risk). For cases with intense and persistent arthralgia, more potent analgesics, physical therapy, and in some cases corticosteroids or disease-modifying antirheumatic drugs may be necessary. These resources are generally available in public health systems, although access to specialists (rheumatologists) and physical therapy may vary depending on local infrastructure. Most cases can be managed on an outpatient basis, with hospitalization reserved for serious complications or vulnerable populations.

3. How long does treatment last?

The duration of treatment varies depending on the disease phase and individual response. In the acute phase (first 10-14 days), symptomatic treatment with analgesics and antipyretics is generally sufficient, with progressive improvement of symptoms. However, a significant proportion of patients develop subacute symptoms (up to 3 months) or chronic symptoms (beyond 3 months), particularly persistent arthralgia. In these cases, treatment may extend for months or even years, including continuous analgesia, regular physical therapy, and in selected cases, medications such as methotrexate or hydroxychloroquine. Patients with risk factors for chronicity (age > 40 years, previous arthropathy, pain intensity in the acute phase) require longer follow-up. Treatment should be individualized, with periodic reassessments for therapeutic adjustment according to clinical evolution.

4. Can this code be used in medical certificates?

Yes, code 1D40 can and should be used in medical certificates when appropriate, as it adequately documents the diagnosis of Chikungunya. In certificates for work leave, the ICD code can be included according to local regulations and patient consent. Chikungunya, especially in its acute phase, frequently causes temporary work incapacity due to high fever and intense arthralgia. The period of leave varies depending on symptom severity and type of work activity, ranging from a few days to weeks in the acute phase. In cases with progression to chronic symptoms, periodic assessments are necessary to determine work capacity. Adequate documentation with code 1D40 facilitates administrative processes and justifies leave when necessary.

5. Can Chikungunya cause permanent symptoms?

Yes, although most patients recover completely, a significant proportion develop chronic symptoms, particularly persistent arthralgia. Studies indicate that joint symptoms may persist for months to years in some patients, with impact on quality of life and functional capacity. Risk factors for chronicity include age over 40 years, presence of previous arthropathy, intensity of arthralgia in the acute phase, and presence of comorbidities. The most common chronic manifestations include persistent joint pain, stiffness, intermittent swelling, and fatigue. Rare permanent complications include neurological sequelae in cases of encephalitis or Guillain-Barré syndrome. Long-term follow-up and appropriate treatment, including physical therapy and pain management, can minimize the impact of chronic symptoms.

6. Is there a vaccine against Chikungunya?

Currently, there is an approved vaccine against Chikungunya in some countries, representing an important advance in the prevention of this disease. The vaccine uses live attenuated virus and demonstrated efficacy in clinical trials. However, availability varies depending on geographic region and local public health policies. In many endemic areas, the vaccine is not yet widely available in routine immunization programs. Prevention continues to be based primarily on vector control measures (elimination of Aedes mosquito breeding sites, use of repellents, window screens, protective clothing) and individual protection. For travelers heading to endemic areas, it is recommended to consult travel medicine services for guidance on vaccine availability and other preventive measures.

7. How to differentiate Chikungunya from dengue without laboratory tests?

Clinical differentiation can be challenging, as both share many symptoms. However, some characteristics may help: arthralgia in Chikungunya tends to be more intense, polyarticular, symmetric, and persistent, often described as incapacitating, while in dengue muscle pain (myalgia) and retro-orbital pain are more prominent. The tourniquet test, when positive, suggests dengue. Hemorrhagic manifestations (petechiae, epistaxis, gingival bleeding) are more common in dengue. The rash in Chikungunya typically appears in the first few days, while in dengue it may appear later. Despite these differences, laboratory confirmation is essential for definitive diagnosis, especially considering the possibility of coinfection and the importance of accurate epidemiological surveillance. In clinical practice, in areas where both circulate, initial management is often similar (symptomatic, hydration, monitoring), with adjustments based on laboratory results.

8. Do pregnant women with Chikungunya present special risks?

Yes, Chikungunya infection during pregnancy requires special attention. Although vertical transmission is rare, it can occur when maternal infection happens close to delivery (intrapartum period), resulting in neonatal infection that can be severe, with neurological, cardiac, and dermatological manifestations. There is no consistent evidence of congenital malformations associated with Chikungunya infection (unlike Zika). Pregnant women with Chikungunya should receive careful prenatal follow-up, with special attention if infection occurs in the third trimester. Symptomatic management should consider fetal safety in medication selection. Newborns of mothers infected close to delivery should be carefully monitored for signs of neonatal infection. Prevention through measures to protect against mosquito bites is particularly important in pregnant women residing in or traveling to endemic areas.

---

Conclusion:

Adequate coding of Chikungunya virus disease using ICD-11 code 1D40 is fundamental for accurate clinical documentation, effective epidemiological surveillance, and public health planning. Understanding when to apply this code, differentiating it from similar conditions, and adequately documenting clinical manifestations allows not only optimized individual care but also contributes to collective knowledge about this arbovirus of growing global importance. Attention to clinical details, laboratory confirmation when possible, and appropriate follow-up, especially in patients with risk factors for chronicity, are essential elements in managing this debilitating condition.

External References

This article was prepared based on reliable scientific sources:

1. 🌍 WHO ICD-11 - Chikungunya virus disease
2. 🔬 PubMed Research on Chikungunya virus disease
3. 🌍 WHO Health Topics
4. 📋 CDC - Centers for Disease Control
5. 📊 Clinical Evidence: Chikungunya virus disease
6. 📋 Ministry of Health - Brazil
7. 📊 Cochrane Systematic Reviews

References verified on 2026-02-02